| Document |
Document Title |
|
WO/2019/119486A1 |
Provided is a kinase inhibitor, comprising a compound of formula I, or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite, or a prodrug thereof. Further provided are a pharmaceutical composition comprising the...
|
|
WO/2019/126443A1 |
The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
|
|
WO/2019/122932A1 |
Compounds of general formula (I): (Formula (I)) wherein R1, R2, X1 and X2 are as defined herein are useful for the treatment of cancer, particularly solid tumours.
|
|
WO/2019/126646A1 |
Described herein are genetic recognition reagents comprising terminal aromatic moieties that bind specifically to a template nucleic acid and concatenate. Also provided are methods of using the genetic recognition reagents, e.g., to trea...
|
|
WO/2019/121408A1 |
The present invention relates to the pyrimidine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are de- fined according to the description, use of pyrimidine compound...
|
|
WO/2019/120263A1 |
The present invention relates to an organic mixture and an application thereof in organic electronic devices. The organic mixture comprises a spirofluorene organic compound containing a fused heterocyclic ring and an aromatic fused heter...
|
|
WO/2019/122151A1 |
The present invention relates a compound of formula (I) in Z-isomer form (Z-(l)) or a compound of formula (I) in E-isomer form (E-(l)) wherein: R2 is a radical of formula (II) and of formula (III); X1, X2, X3, X4 and X5 are CR3 and N; Y1...
|
|
WO/2019/121547A1 |
The invention relates to substituted thiophenyl uracils of general formula (I) or the salts thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for con...
|
|
WO/2019/117148A1 |
The purpose of the present invention is to provide a novel low molecular-weight compound having orexin receptor agonist activity that is expected to be useful for the prevention or treatment of narcolepsy, etc. The present invention prov...
|
|
WO/2019/115019A1 |
The application relates to a process for the preparation of compound of formula (1) or a salt thereof (i.e. elagolix): The application also relates to solid crystalline forms of intermediates used in the process.
|
|
WO/2019/112968A1 |
The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.
|
|
WO/2019/111225A1 |
Compounds and compositions are provided having the structure of Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein T, T', U, U', V, W, R1, R2, R3', n, o, o', o'', and o''' are as defined herein....
|
|
WO/2019/113071A1 |
Heterobifunctional small molecules including anaplastic lymphoma kinase (ALK) ligand conjugated to a degradation/disruption tag through a linker, which selectively degrade/disrupt ALK, ALK fusion proteins, and/or ALK mutant proteins, and...
|
|
WO/2019/101551A1 |
The present invention relates to phenylethers of formula (I) or their agriculturally acceptable salts or derivatives, wherein the variables are defined according to the description, processes and intermediates for preparing the phenyleth...
|
|
WO/2019/101647A1 |
The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I)5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for pr...
|
|
WO/2019/101053A1 |
Disclosed are a new crystal form of a rosuvastatin calcium intermediate, [4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfona
mido)-5-pyrimidyl]triphenylphosphonium bromide, and a preparation method therefor. The XRPD spectrum of...
|
|
WO/2019/101039A1 |
Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tau...
|
|
WO/2019/096209A1 |
Provided are a chiral 1,3-diarylimidazolium salt carbene precursor (S), a synthesis method therefor, a metal salt compound, and an application thereof. The chiral 1,3-diarylimidazolium salt carbene precursor catalyzes a reaction between ...
|
|
WO/2019/094641A1 |
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or amelior...
|
|
WO/2019/090558A1 |
Disclosed is a 5-fluorouracil derivative having the molecular structure shown in general formula VI, in which Ra and Rb groups are an alkoxy group or a fluorine-substituted alkoxy group having 1, 2, 3, or 4 carbon atoms, and are mono-, b...
|
|
WO/2019/090081A1 |
Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
|
|
WO/2019/089902A1 |
The present application is directed, in part, to compounds, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof, for modulating the activity of Sigma1 receptor. The present application...
|
|
WO/2019/087214A1 |
The compounds of Formula Ib, Formula Ia, and Formula I are described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The process of preparation of the compo...
|
|
WO/2019/085916A1 |
A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.
|
|
WO/2019/079599A1 |
An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.
|
|
WO/2019/076343A1 |
Disclosed are a PD-1/PD-L1 small-molecule inhibitor and a preparation method therefor and use thereof. In particular, disclosed are a compound which has a structure as shown in formula L, a stereoisomer or a tautomer thereof, or a pharma...
|
|
WO/2019/076904A1 |
The application relates to compounds of formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activi...
|
|
WO/2019/079540A1 |
The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) by administering ...
|
|
WO/2019/078246A1 |
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...
|
|
WO/2019/072785A1 |
The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufac...
|
|
WO/2019/071351A1 |
A novel class of fluorinated derivatives of Formula I have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders. The compounds of Formula I display excellent brain penetration and an improved ...
|
|
WO/2019/068726A1 |
The present invention relates to a cellular transport system for bringing a sulfonic acid construct which carries a cargo into a cell and releasing the cargo in the cell's cytoplasm, the cellular transport system comprising: (i) a sulfon...
|
|
WO/2019/070169A1 |
The invention relates to a water-soluble liophilised form of (bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl)-
(4-nitrophenyl)methane) which has hepatoprotective activity and is designed to be used in medicine for the treatmen...
|
|
WO/2019/070709A1 |
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.
|
|
WO/2019/070167A1 |
The present group of inventions relates to novel compounds having formula (I), and to the salts, solvates or stereoisomers thereof, as well as to a pharmaceutical composition, a method of inhibiting the biological activity of epidermal g...
|
|
WO/2019/066340A1 |
The present invention relates to an organic compound represented by formula 1, an organic optoelectronic device comprising the same, and a display device.
|
|
WO/2019/062876A1 |
Provided are a fluorescent probe, a preparation method therefor and a use thereof. The fluorescent probe responds to viscosity sensitively and specifically, can be used for the specific fluorescence label of proteins, and can also be use...
|
|
WO/2019/063634A1 |
The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which ...
|
|
WO/2019/063704A1 |
The present invention covers substituted 3-Phenylquinazolin-4(3H)-one compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, phar...
|
|
WO/2019/063708A1 |
The present invention covers substituted 3-Phenylquinazolin-4(3H)-one compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, phar...
|
|
WO/2019/067543A1 |
The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR media...
|
|
WO/2019/058289A1 |
The invention relates to peptide conjugates of Formula (I). The peptide conjugates of the invention have activity as MAIT agonists. The peptide conjugates of the invention also enhance immune responses and therefore are effective vaccine...
|
|
WO/2019/057720A1 |
The present invention relates to herbicidally active pyridyl-/pyrimidyl-pyridine derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal composition...
|
|
WO/2019/057721A1 |
The present invention relates to herbicidally active pyridyl-/pyrimidyl-pyrimidine derivatives. The invention further provides processes and intermediates used for the preparation of such derivatives. The invention further extends to her...
|
|
WO/2019/055528A1 |
The present invention relates to compositions and methods for the treatment of cancer and other diseases associated with mitochondrial dysfunction, including but not limited to, neurodegenerative disease, brain injuries, and certain non-...
|
|
WO/2019/055832A1 |
Provided herein are compounds of Formula (I) and (II) and their salts, and compositions comprising such compounds that are useful for useful for modulating neutral sphingomyelinase 2 (n-SMase2) in cells. Also disclosed herein are methods...
|
|
WO/2019/053427A1 |
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof,wherein the ring containing Q1to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.
|
|
WO/2019/052519A1 |
Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumo...
|
|
WO/2019/049049A1 |
The invention provides certain nicotine salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, certain nicotine salt-co-crystals are described, including nicotine and two different coformers. The ...
|
|
WO/2019/051396A1 |
Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR...
|
